Telo Genomics reports study showing blood-based TELO-MRD detects circulating plasma cells in all clonoSEQ-positive myeloma cases reviewed

• Telo Genomics reported additional clinical research results for its blood-based TELO-MRD program in multiple myeloma.
• Findings were presented now, not flagged for a future conference or publication in the announcement.
• In matched samples, the blood test detected circulating malignant plasma cells in all bone-marrow NGS MRD-positive cases reviewed.
• It also flagged circulating plasma cells in some cases called MRD-negative or non-evaluable by the bone-marrow NGS method.
• TELO-MRD remains in development, with a targeted commercial application by the end of calendar 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telo Genomics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609290330NEWSFILECNPR____20260929_316474_1) on September 29, 2026, and is solely responsible for the information contained therein.